BioNTech Shifts Strategy Toward Tumor-Centric Oncology with Key Clinical Data
During its Q1 earnings call, BioNTech outlined a new tumor-centric oncology strategy focused on combination therapies and highlighted encouraging clinical data for pumitamab in early lung cancer. The company also reaffirmed 2026 revenue guidance despite lower-than-expected first-quarter results.
Topics: clinical_trials financials oncology share_buyback workforce_reduction